Cancel anytime
Artivion Inc (AORT)AORT
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: AORT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 3.1% | Upturn Advisory Performance 2 | Avg. Invested days: 38 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 3.1% | Avg. Invested days: 38 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.13B USD |
Price to earnings Ratio - | 1Y Target Price 33.17 |
Dividends yield (FY) - | Basic EPS (TTM) -0.03 |
Volume (30-day avg) 213504 | Beta 1.75 |
52 Weeks Range 16.48 - 30.00 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.13B USD | Price to earnings Ratio - | 1Y Target Price 33.17 |
Dividends yield (FY) - | Basic EPS (TTM) -0.03 | Volume (30-day avg) 213504 | Beta 1.75 |
52 Weeks Range 16.48 - 30.00 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-07 | When AfterMarket |
Estimate -0.06 | Actual -0.05 |
Report Date 2024-11-07 | When AfterMarket | Estimate -0.06 | Actual -0.05 |
Profitability
Profit Margin -0.22% | Operating Margin (TTM) 8.26% |
Management Effectiveness
Return on Assets (TTM) 2.29% | Return on Equity (TTM) -0.29% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE 169.49 |
Enterprise Value 1435844799 | Price to Sales(TTM) 2.93 |
Enterprise Value to Revenue 3.73 | Enterprise Value to EBITDA 22.79 |
Shares Outstanding 41919900 | Shares Floating 34531514 |
Percent Insiders 5.51 | Percent Institutions 87.11 |
Trailing PE - | Forward PE 169.49 | Enterprise Value 1435844799 | Price to Sales(TTM) 2.93 |
Enterprise Value to Revenue 3.73 | Enterprise Value to EBITDA 22.79 | Shares Outstanding 41919900 | Shares Floating 34531514 |
Percent Insiders 5.51 | Percent Institutions 87.11 |
Analyst Ratings
Rating 4.67 | Target Price 25.3 | Buy 2 |
Strong Buy 4 | Hold - | Sell - |
Strong Sell - |
Rating 4.67 | Target Price 25.3 | Buy 2 | Strong Buy 4 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Artivion Inc. Overview:
Company Profile:
History and Background:
Artivion Inc. (NASDAQ: ATRA) is a clinical-stage biopharmaceutical company founded in 2017. It emerged from the University of Pittsburgh and the University of Washington to develop novel therapies for the treatment of life-threatening viral diseases.
Core Business Areas:
Artivion focuses on developing therapies for:
- Hepatitis B Virus (HBV): Artivion's lead product candidate, ART123, is a capsid assembly modulator (CAM) designed to treat chronic HBV infection.
- Human Immunodeficiency Virus (HIV): The company is also developing ART116, a next-generation HIV-1 maturation inhibitor currently in preclinical development.
Leadership Team and Corporate Structure:
- Patrick C. Ledger, Ph.D., Chief Executive Officer and President: Dr. Ledger brings extensive experience in the pharmaceutical industry, having previously held leadership positions at Gilead Sciences and Bristol-Myers Squibb.
- Paul E. Lichter, Chief Financial Officer: Mr. Lichter has over 20 years of experience in finance and accounting, including roles at Gilead Sciences and Nektar Therapeutics.
- John H. Beigel, M.D., Chief Medical Officer: Dr. Beigel is a renowned infectious disease expert with extensive experience in clinical research and development.
Top Products and Market Share:
ART123:
- In Phase 2b clinical trials for the treatment of chronic HBV infection.
- Holds Orphan Drug Designation from the FDA and EMA.
- Market share potential is significant, considering the large population of individuals infected with HBV globally.
ART116:
- In preclinical development for the treatment of HIV-1 infection.
- Differentiates itself from existing HIV therapies by targeting a novel mechanism of action.
- Market share potential is high, considering the ongoing need for new and effective HIV therapies.
Total Addressable Market:
The global market for HBV and HIV therapies is substantial.
- HBV: Approximately 296 million people are chronically infected with HBV, representing a significant market opportunity for ART123.
- HIV: Around 38 million people globally are living with HIV, highlighting the need for new treatment options like ART116.
Financial Performance:
Revenue and Profitability:
As a clinical-stage company, Artivion currently has no product revenue. Most of its expenses are related to research and development. Net losses are expected until ART123 receives regulatory approval and is commercialized.
Cash Flow and Balance Sheet:
Artivion has raised significant capital through public offerings and private placements. As of June 30, 2023, the company had cash and cash equivalents of $155.4 million, providing sufficient runway for ongoing clinical trials and operations.
Dividends and Shareholder Returns:
Artivion is currently not paying dividends as it focuses on investing in research and development. Shareholder returns have primarily been driven by changes in the company's stock price.
Growth Trajectory:
Historical Growth:
Artivion has experienced significant growth in recent years, primarily driven by successful clinical trial advancements and increased investor interest.
Future Growth Projections:
The success of ART123 and ART116 in clinical trials is crucial for future growth. Regulatory approval and commercialization of these products could significantly increase revenue and drive share price appreciation.
Market Dynamics:
Industry Trends:
The market for HBV and HIV therapies is evolving rapidly, driven by advancements in drug development and increasing access to healthcare. There is a strong demand for safe and effective therapies with novel mechanisms of action.
Artivion's Positioning:
Artivion is well-positioned within the industry with its promising pipeline of innovative therapies. The company's focus on unmet medical needs and differentiated product candidates positions it for potential success.
Competitors:
Key Competitors:
- Gilead Sciences (GILD)
- Bristol-Myers Squibb (BMY)
- ViiV Healthcare (VEEV)
- Merck & Co. (MRK)
Competitive Advantages and Disadvantages:
Artivion's competitive advantages include its novel drug candidates, experienced leadership team, and strong financial backing. However, the company faces strong competition from established players in the pharmaceutical industry.
Potential Challenges and Opportunities:
Challenges:
- Clinical Trial Success: Artivion's future success hinges on the successful completion of ongoing clinical trials.
- Regulatory Approval: Obtaining regulatory approval for ART123 and ART116 is crucial for commercialization.
- Competition: Facing competition from established pharmaceutical companies with larger resources and broader product portfolios.
Opportunities:
- Significant Market Potential: Targeting large global markets with unmet medical needs presents a significant opportunity for growth.
- Novel Drug Candidates: Artivion's innovative therapies have the potential to become best-in-class treatment options.
- Strategic Partnerships: Collaborating with other companies could accelerate development and commercialization efforts.
Recent Acquisitions:
Artivion has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of financial health, market position, and future prospects, Artivion Inc. receives a 7 out of 10 rating. This indicates a potentially promising investment opportunity, but investors should carefully consider the company's risks and uncertainties before making investment decisions.
Sources and Disclaimers:
This overview is based on information gathered from publicly available sources, including:
- Artivion Inc. Investor Relations website
- SEC filings
- Market research reports
This information is intended for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artivion Inc
Exchange | NYSE | Headquaters | Kennesaw, GA, United States |
IPO Launch date | 1993-02-12 | Chairman, President & CEO | Mr. James Patrick Mackin |
Sector | Healthcare | Website | https://artivion.com |
Industry | Medical Devices | Full time employees | 1500 |
Headquaters | Kennesaw, GA, United States | ||
Chairman, President & CEO | Mr. James Patrick Mackin | ||
Website | https://artivion.com | ||
Website | https://artivion.com | ||
Full time employees | 1500 |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.